Key facts
- Akelos’s last known valuation is $45.0M (Oct 2022).
- It has raised $3.6M across 2 recorded rounds; the latest was Seed Round ($1.5M) in Mar 2026.
- Notable investors include National Institutes of Health, Cornell University, National Institutes of Neurological Disorders and Stroke.
- Akelos has filed 3 Form Ds with the SEC since 2018, most recently Oct 2022 ($6K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Akelos
Funding rounds
2 roundsAbout Akelos
Developer of non-opioid pharmaceutical candidates designed to treat neuropathic pain. The company offers clinical-stage small-molecule therapeutics based on translational neuroscience and non-narcotic mechanisms of action, supported by preclinical and clinical programs across neuropathic pain indications, enabling healthcare providers and patients with chronic neuropathic pain to access emerging treatment options that address unmet medical needs.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2018
- Employees
- 5
- Website
- akelosinc.com/
- Ownership
- Privately Held (backing)
Akelos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Akelos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Akelos in its N-PORT filings yet. We sweep new filings monthly.